HB Wealth Management LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

HB Wealth Management LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,129 shares of the biopharmaceutical company’s stock after buying an additional 161 shares during the quarter. HB Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $1,516,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the stock. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Fairfield Financial Advisors LTD acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $37,000. Truvestments Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $39,000. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $42,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.7 %

NASDAQ REGN opened at $681.58 on Tuesday. The company’s fifty day simple moving average is $738.60 and its 200-day simple moving average is $948.80. The stock has a market cap of $74.90 billion, a P/E ratio of 16.87, a PEG ratio of 1.60 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Wall Street Analysts Forecast Growth

REGN has been the subject of several recent analyst reports. Piper Sandler lowered their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. lowered their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Barclays lowered their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Finally, Citigroup cut their price objective on shares of Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating on the stock in a report on Tuesday, January 14th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.